Wie hoch ist der Preis für Freeline Therapeutics Holdings plc (FRLN)

Preis für Freeline Therapeutics Holdings plc (FRLN) ist $6.48

Wie hoch ist die Marktkapitalisierung für Freeline Therapeutics Holdings plc (FRLN)

Marktkapitalisierung für Freeline Therapeutics Holdings plc (FRLN) ist $15.41M

Freeline Therapeutics Holdings plc (FRLN) Gewinne

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.

Jahr	Gewinn	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

Gewinn

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Gewinn	Gewinnunterschied	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$1.61B	-	AU
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	$3.01B	-	BE

Unternehmen

Gewinn

Gewinnunterschied

Land